MARKSANS PHARMA
|
MARKSANS PHARMA Last 5 Year Financial Ratios History
[Consolidated]
Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
---|---|---|---|---|---|
Operational & Financial Ratios | |||||
Earnings Per Share (Rs) | 8.40 | 6.92 | 5.88 | 4.51 | 5.76 |
CEPS(Rs) | 10.28 | 8.59 | 7.00 | 5.66 | 6.71 |
DPS(Rs) | 0.80 | 0.60 | 0.50 | 0.25 | 0.25 |
Book NAV/Share(Rs) | 54.44 | 45.57 | 38.51 | 27.10 | 21.66 |
Tax Rate(%) | 24.08 | 25.65 | 21.42 | 24.52 | 21.06 |
Margin Ratios | |||||
Core EBITDA Margin(%) | 19.25 | 20.03 | 16.64 | 16.71 | 24.40 |
EBIT Margin(%) | 18.77 | 18.99 | 17.00 | 16.53 | 22.28 |
Pre Tax Margin(%) | 18.35 | 18.50 | 16.56 | 15.98 | 21.71 |
PAT Margin (%) | 13.93 | 13.75 | 13.01 | 12.06 | 17.14 |
Cash Profit Margin (%) | 16.97 | 17.00 | 15.55 | 14.95 | 19.74 |
Performance Ratios | |||||
ROA(%) | 12.93 | 12.93 | 13.78 | 12.94 | 22.40 |
ROE(%) | 16.89 | 16.53 | 18.59 | 18.72 | 31.33 |
ROCE(%) | 22.50 | 22.40 | 22.89 | 23.82 | 39.76 |
Asset Turnover(x) | 0.93 | 0.94 | 1.06 | 1.07 | 1.31 |
Sales/Fixed Asset(x) | 2.16 | 2.33 | 2.62 | 2.42 | 2.49 |
Working Capital/Sales(x) | 1.59 | 1.55 | 1.53 | 1.83 | 2.30 |
Efficiency Ratios | |||||
Fixed Capital/Sales(x) | 0.46 | 0.43 | 0.38 | 0.41 | 0.40 |
Receivable days | 65.99 | 69.35 | 72.63 | 78.56 | 67.57 |
Inventory Days | 97.24 | 87.89 | 81.36 | 97.65 | 84.73 |
Payable days | 91.59 | 87.70 | 85.31 | 93.88 | 85.57 |
Valuation Parameters | |||||
PER(x) | 26.48 | 21.89 | 11.99 | 10.10 | 8.67 |
PCE(x) | 21.62 | 17.65 | 10.07 | 8.05 | 7.44 |
Price/Book(x) | 4.08 | 3.33 | 1.83 | 1.68 | 2.31 |
Yield(%) | 0.36 | 0.40 | 0.71 | 0.55 | 0.50 |
EV/Net Sales(x) | 3.58 | 2.86 | 1.36 | 1.04 | 1.35 |
EV/Core EBITDA(x) | 15.68 | 12.23 | 6.32 | 5.18 | 5.35 |
EV/EBIT(x) | 18.22 | 14.32 | 7.27 | 6.08 | 5.97 |
EV/CE(x) | 3.77 | 2.97 | 1.41 | 0.94 | 1.51 |
M Cap / Sales | 3.84 | 3.15 | 1.72 | 1.25 | 1.49 |
Growth Ratio | |||||
Net Sales Growth(%) | 20.46 | 17.56 | 24.23 | 8.33 | 21.33 |
Core EBITDA Growth(%) | 17.68 | 27.69 | 32.55 | -13.16 | 79.82 |
EBIT Growth(%) | 18.61 | 25.36 | 35.48 | -17.47 | 86.93 |
PAT Growth(%) | 21.51 | 18.68 | 42.02 | -21.68 | 97.54 |
EPS Growth(%) | 21.32 | 17.80 | 30.32 | -21.77 | 101.63 |
Financial Stability Ratios | |||||
Total Debt/Equity(x) | 0.01 | 0.01 | 0.02 | 0.04 | 0.02 |
Current Ratio(x) | 4.62 | 4.78 | 4.91 | 3.22 | 3.02 |
Quick Ratio(x) | 2.85 | 3.19 | 3.49 | 2.11 | 1.67 |
Interest Cover(x) | 44.22 | 38.80 | 37.99 | 30.31 | 38.84 |
Total Debt/Mcap(x) | - | - | 0.01 | 0.02 | 0.01 |
Compare Financial Ratios of peers of MARKSANS PHARMA
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
MARKSANS PHARMA | ₹10,312.6 Cr | -4.1% | -13% | 13% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹410,466.0 Cr | 1.7% | 2% | -0.6% | Stock Analytics | |
DIVIS LABORATORIES | ₹177,298.0 Cr | 0.4% | -2% | 37.3% | Stock Analytics | |
TORRENT PHARMACEUTICALS | ₹127,538.0 Cr | 6% | 10.5% | 13.6% | Stock Analytics | |
CIPLA | ₹127,140.0 Cr | 6.8% | 4.6% | -0.5% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹108,500.0 Cr | 4.2% | 1.3% | -6.7% | Stock Analytics |
MARKSANS PHARMA Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
MARKSANS PHARMA | -4.1% |
-13% |
13% |
SENSEX | -1% |
-3.2% |
1.6% |
You may also like the below Video Courses